Bloqueadores dos receptores da angiotensina II em Síndrome de Marfan

No seguimento de longo prazo do estudo randomizado COMPARE (COzaar in Marfan Patients Reduces aortic Enlargement), que testou a adição de Losartana ao tratamento habitual (Beta-bloqueadores em 71% dos pacientes), os pacientes que utilizaram Losartana durante todo o período de seguimento tiveram menos desfechos clínicos desfavoráveis como morte e dissecção de aorta.

Fonte:

Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial – European Heart Journal

Estudo Original:

Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial – European Heart Journal

Comentário no Twitter

Clinical benefit of combined losartan and β-blocker treatment in patients with Marfan syndrome – follow-up of the COMPARE trial https://t.co/lfhrqvacLq@escardio #EHJ #ESC_Young #cardiotwitter @ehj_ed pic.twitter.com/XEHiAfvLOA

— European Society of Cardiology Journals (@ESC_Journals) June 23, 2020